US2008171735A1PendingUtilityA1
SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
Assignee: BRISTOL MYERS SQUIBB PHARMA COPriority: Dec 24, 1998Filed: Mar 10, 2008Published: Jul 17, 2008
Est. expiryDec 24, 2018(expired)· nominal 20-yr term from priority
Inventors:Richard E. Olson
A61P 43/00C07D 243/12C07D 223/16C07D 243/14C07D 401/04A61P 25/00C07D 243/24A61P 25/28
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.
Claims
exact text as granted — not AI-modified1 - 24 . (canceled)
25 . A process for preparing a compound of Formula (I),
or a stereoisomer or a pharmaceutically acceptable salt thereof, comprising the steps of: coupling a solid phase bound succinic acid derivative by amide bond synthesis to an aminolactam mediated by O-(7-azabenzotriazol-1-yl)-N,N, N′,N′-tetramethyluronium hexafluorophosphate (HATU), O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), benzotriazol-1-yloxytris-(dimethylamino)-phosphonium hexafluorophosphate (BOP), EDC, CDI, or DCC, the product being liberated from the solid phase by employing dilute trifluoroacetic acid in CH 2 Cl 2 ; and purified by chromatography to obtain a structure;
wherein:
A is O;
Q is —NR 1 R 2 ;
R 1 is selected from:
H;
C 1 -C 6 alkyl substituted with 0-3 R 1a ;
C 3 -C 10 carbocycle substituted with 0-3 R 1b ;
aryl substituted with 0-3 R 1b ; and
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 1b ;
R 1a , at each occurrence, is independently selected from H, C 1 -C 6 alkyl Cl, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 , CF 3 ;
C 3 -C 10 carbocycle substituted with 0-3 R 1b ;
aryl substituted with 0-3 R 1b ; and
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 1b ;
R 1b , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 haloalkyl, and C 1 -C 4 haloalkoxy;
R 2 is selected from H, C 1 -C 6 alkyl, C 3 -C 10 carbocycle, C6-C 10 aryl, and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur;
R 3 is —(CR 7 R 7a ) n —R 4 ,
—(CR 7 R 7 a′) n —S—(CR 7 R 7a )M-R 4 ,
—(CR 7 R 7a )—O—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —N(R 7b )—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —S(═O)—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —S(═O) 2 —(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —C(═O)—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —N(R 7b )C(═O)—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —C(═O)N(R 7b )—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —N(R 7b )S(═O) 2 —(CR 7 R 7a ) m —R 4 or
—(CR 7 R 7a ) n —S(═O) 2 N(R 7b )—(CR 7 R 7a ) m —R 4 ;
n is 0, 1, 2, or 3;
m is Q, 1,2, or 3;
R 3a is H, OH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyl or C 2 -C 4 alkenyloxy;
R 4 is H, OH, OR 14a ,
C 1 -C 6 alkyl substituted with 0-3 R 4a ,
C 2 -C 6 alkenyl substituted with O-3 R 4a ,
C 2 -C 6 alkynyl substituted with 0-3 R 4a
C 3 -C 10 carbocycle substituted with 0-3 R 4b ,
aryl substituted with 0-3 R 4b , or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 4b ;
R 4a , at each occurrence, is independently selected from H, F, Cl, Br, I, CF 3 ,
C 3 -C 10 carbocycle substituted with 0-3 R 4b ,
aryl substituted with 0-3 R 4b , and
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 4b ;
R 4b , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 ,
C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl,
C 1 -C 4 haloalkoxy, and C 1 -C 4 haloalkyl-S—;
R 5 is H, OR 14 ;
C 1 -C 6 alkyl substituted with 0-3 R 5b ;
C 1 -C 6 alkoxy substituted with 0-3 R 5b :
C 2 -C 6 alkenyl substituted with 0-3 R 5b ;
C 2 -C 6 alkynyl substituted with 0-3 R 5b ,
C 3 -C 10 carbocycle substituted with 0-3 R 5c ;
aryl substituted with 0-3 R 5c ; or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 5c ;
R 5a is H, OH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyl, or C 2 -C 4 alkenyloxy;
R 5b , at each occurrence, is independently selected from:
H, C 1 -C 6 alkyl, CF 3 , OR 14 , C, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 ;
C 3 -C 10 carbocycle substituted with 0-3 R 5c ;
aryl substituted with 0-3 R 5c ; and
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 5c ;
R 5c , at each occurrence, is independently selected from H, OH, Cl, F, Br, L, CN, NO 2 ,
NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 ,
C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl,
C 1 -C 4 haloalkoxy, and C 1 -C 4 haloalkyl-S;
R 6 is H;
C 1 -C 6 alkyl substituted with 0-3 R 6a ;
C 3 -C 10 carbocycle substituted with 0-3 R 6b ; or
aryl substituted with 0-3 R 6b ;
R 6a , at each occurrence, is independently selected from H, C 1 -C 6 alkyl, OR 14 , Cl, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 , aryl and CF 3 ;
R 6b , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , C 1 -C 6 alkyl, C 1 -C 4 alkoxy, CT-C4 haloalkyl, and C 1 -C 4 haloalkoxy;
R 7 , at each occurrence, is independently selected from H, OH, Cl, F, Br, J, CN, NO 2 , CF 3 , phenyl and C 1 -C 4 alkyl;
R 7a , at each occurrence, is independently selected from H, OH, Cl, F. Br, I, CN, NO 2 , CF 3 , and C 1 -C 4 alkyl;
R 7b is selected from H and C 1 -C 4 alkyl;
Ring B is
R 10 is H, C(═O)R 17 , C(═O)OR 17 , C(═O)NR 18 R 19 ,
S(═O) 2 NR 18 R 19 , S(═O) 2 R 17 ;
C 1 -C 6 alkyl optionally substituted with 0-3 R 10a ;
aryl substituted with 0-4 R 10b ;
C 3 -C 10 carbocycle substituted with 0-3 R 10b ; or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 10b ;
R 10a , at each occurrence, is independently selected from H, C 1 -C 6 alkyl, OR 14 , Cl, F, Br, I, ═O, CN, NO NR 15 R 16 , CF 3 , and aryl substituted with 0-4 R 1b .
R 10b , at each occurrence, is independently selected from H, OH, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, and C 1 -C 4 haloalkyl-S—;
Z is H;
C 1 -C 8 alkyl substituted with 1-3 R 12 ;
C 2 -C 4 alkenyl substituted with 1-3 R 12 ;
C 2 -C 4 alkynyl substituted with 1-3 R 12 ;
C 1 -C 8 alkyl substituted with 0-3 R 12a ;
C 2 -C 4 alkenyl substituted with 0-3 R 12a ;
C 2 -C 4 alkynyl substituted with 0-3 R 12a ;
aryl substituted with 0-4 R 12b ;
C 3 -C 10 carbocycle substituted with 0-4 R 12b ; or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 12b ;
R 12 , at each occurrence, is independently selected from aryl substituted with 0-4 R 12b ;
C 3 -C 10 carbocycle substituted with 0-4 R 12b ; and
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 12 b;
R 12a , at each occurrence, is independently selected from
H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , C(═O)NR 15 R 16 , CF 3 , acetyl, SCH 3 ,
S(O)CH 3 , S((O) 2 CH 3 ,
C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl,
C 1 -C 4 haloalkoxy, and C 1 -C 4 haloalkyl-S;
R 12b , at each occurrence, is independently selected from
H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(—O)CH 3 , SO) 2 CH 3 ,
C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl,
C 1 -C 4 haloalkoxy, and C 1 -C 4 haloalkyl-S;
R 13 , at each occurrence, is independently selected from
H, OH, CT-C6 alkyl, C 1 -C 4 alkoxy, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , and CF 3 ;
R 14 is H, phenyl, benzyl, C 1 -C 6 alkyl, C 2 -C 6 alkoxyalkyl, or C 3 -C 6 cycloalkyl;
R 14a is H, phenyl, benzyl, or C 1 -C 4 alkyl;
R 15 , at each occurrence, is independently selected from H, C 1 -C 6 alkyl, benzyl, phenethyl, (C 1 -C 6 alkyl)-C(═O)—, and (C 1 -C 6 alkyl)-SO) 2 —;
R 16 , at each occurrence, is independently selected from
H, OH, C 1 -C 6 alkyl, benzyl, phenethyl,
(C 1 -C 6 alkyl)-C(═O)—, and (C 1 -C 6 alkyl)-S(O) 2 —;
R 17 is H, C 1 -C 6 alkyl, C 2 -C 6 alkoxyalkyl,
aryl substituted by 0-4 R 17a , or
—CH 2 -aryl substituted by 0-4 R 17a ;
R 17a , at each occurrence, is independently methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, —OH, F, Cl, Br, I, CF 3 , OCF 3 , SCH 3 , S(O)CH 3 , SO 2 CH 3 , —NH 2 , —N(CH 3 ) 2 , and C 1 -C 4 haloalkyl;
R 18 is selected from
H, C 1 -C 6 alkyl, phenyl, benzyl, phenethyl,
(C 1 -C 6 alkyl)-C(═O)—, and (C 1 -C 6 alkyl)-S(═O) 2 —; and
R 19 is selected from
H, OH, C 1 -C 6 alkyl, phenyl, benzyl, phenethyl,
(C 1 -C 6 alkyl)-C(═O)—, and (C 1 -C 6 alkyl)-S(═O) 2 —;
provided, when R 13 is H,
then Z is H;
C 4 -C 9 alkyl substituted with 1-3 R 12 ;
C 2 -C 4 alkenyl substituted with 1-3 R 12 ;
C 2 -C 4 alkynyl substituted with 1-3 R 12 ;
C 1 -C 9 alkyl substituted with 0-3 R 12a —
C 2 -C 4 alkenyl substituted with 0-3 R 12a ; or
C 2 -C 4 alkynyl substituted with 0-3 R 12a .
26 . A process according to claim 1 , for preparing a compound of Formula (Ia):
a stereoisomer, or a pharmaceutically acceptable salt thereof,
wherein:
Z is H;
C 1 -C 8 alkyl substituted with 0-3 R 12a ;
C 2 -C 4 alkenyl substituted with 0-3 R 12a ; or
C 2 -C 4 alkynyl substituted with 0-3 R 12a .
27 . A process according to claim 1 for preparing a compound, of Formula (Ia):
a stereoisomer, or a pharmaceutically acceptable salt thereof,
wherein:
Z is C 1 -C 8 alkyl substituted with 1-3 R 12 ;
C 2 -C 4 alkenyl substituted with 1-3 R 12 ;
C 2 -C 4 alkynyl substituted with 1-3 R 12 ;
aryl substituted with 0-4 R 12b ;
C 3 -C 10 carbocycle substituted with 0-4 R 12b ; or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 12b ;
provided, when R 13 is H,
then Z is C 4 -C 8 alkyl substituted with 1-3 R 2 ;
C 2 -C 4 alkenyl substituted with 1-3 R 12 ; or
C 2 -C 4 alkynyl substituted with 1-3 R 12 ; and
provided, when ring B is a 1,3,4,5-tetrahydro-1-(Z)-5-(R 10 )-2,4-dioxo-2H-1,5-diazepin-3-yl core, and R 11 is H; then
R 10 is H, C(═O)R 17 , C(═O)OR 17 , C(═O)NR 18 R 19 ,
S(═O) 2 NR 18 R 19 , S(═O) 2 R 17 ; or
C 1 -C 6 alkyl optionally substituted with 0-3 R 10a ; and
R 10a , at each occurrence, is independently selected from
H, C 1 -C 6 alkyl, OR 14 , Cl, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 , and CF 3 .
28 . A process according to claim 1 for preparing a compound, of Formula (Ia):
a stereoisormer, or a pharmaceutically acceptable salt thereof,
wherein:
R 3 is —(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —S—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —O—(CR 71 R 7a ) m —R 4 , or
—(CR 7 R 7a ) n —N(R 7b )—(CR 7 R 7a ) m —R 4 ;
n is 0, 1, or 2;
m is 0, 1, or 2;
R 3a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, allyl, or 3-buten-1-yl;
R 4 is H, OH, OR 14a ,
C 1 -C 6 alkyl substituted with 0-3 R 4a ,
C 2 -C 6 alkenyl substituted with 0-3 R 4a ,
C 2 -C 6 alkynyl substituted with 0-3 R 4a ,
C 3 -C 10 carbocycle substituted with 0-3 R 4b ,
aryl substituted with 0-3 R 4b , or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 4b ;
R 4a , at each occurrence, is independently selected from H, F, Cl, Br, I, CF 3 ,
C 3 -C 10 carbocycle substituted with 0-3 R 4b ,
aryl substituted with 0-3 R 4b , and
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 4b ;
R 4b , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, and C 1 -C 4 haloalkoxy;
R 5 is H, OR 14 ;
C 1 -C 6 alkyl substituted with 0-3 R 5b ;
C 1 -C 6 alkoxy substituted with 0-3 R 5b ;
C 2 -C 6 alkenyl substituted with 0-3 R 5b ;
C 2 -C 6 alkynyl substituted with 0-3 R 5b ;
C 1 -C 10 carbocycle substituted with 0-3 R 5c ;
aryl substituted with 0-3 R 5c ; or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 5c ;
R 5a is H or C 1 -C 4 alkyl;
R 5b , at each occurrence, is independently selected from:
H, C 1 -C 6 alkyl, CF 3 , OR 14 , Cl, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 ;
C 3 -C 10 carbocycle substituted with 0-3 R 5c ;
aryl substituted with 0-3 R 5c ; and
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 5c ;
R 5c , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, and C 1 -C 4 haloalkoxy;
R 6 is H, methyl, or ethyl;
R 7 , at each occurrence, is independently selected from
H, OH, Cl, F, Br, I, CN, NO 2 , CF 3 , phenyl, and C 1 -C 4 alkyl;
R 7a , at each occurrence, is independently selected from
H, OH, Cl, F, Br, I, CN, NO 2 , CF 3 , and C 1 -C 4 alkyl;
R 7b is selected from H, methyl, ethyl, propyl, and butyl;
Ring B is
R 10 is H, C(═O)R 17 , C(═O)OR 17 , C(═O)NR 18 R 19 ,
S(═O) 2 NR 18 R 19 , S(═O) 2 R 17 ;
C 1 -C 6 alkyl optionally substituted with 0-2 R 10a ;
aryl substituted with 0-4 R 10b b;
C 3 -C 10 carbocycle substituted with 0-3 R 10b ; or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 10b ;
R 10a , at each occurrence, is independently selected from H, C 1 -C 6 alkyl, OR 14 , Cl, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 , CF 3 , and phenyl substituted with 0-4 R 10b ;
R 10b , at each occurrence, is independently selected from H, OH, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , and CF 3 ;
Z is C 1 -C 6 alkyl substituted with 1-3 R 12 ;
C 2 -C 4 alkenyl substituted with 1-3 R 12 ;
C 2 -C 4 alkynyl substituted with 1-3 R 12 ;
aryl substituted with 0-4 R 12b ;
C 3 -C 10 carbocycle substituted with 0-4 R 12b ; or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 12b ;
R 12 , at each occurrence, is independently selected from
aryl substituted with 0-4 R 12b ;
C 3 -C 10 carbocycle substituted with 0-4 R 12b ; and 5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 12 b;
R 12b , at each occurrence, is independently selected from
H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, and C 1 -C 4 haloalkoxy;
R 13 , at each occurrence, is independently selected from
H, OH, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , and CF 3 ;
R 14 is, at each occurrence, H, phenyl, benzyl, C 1 -C 6 alkyl, or C 2 -C 6 alkoxyalkyl;
R 14a is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
R 15 , at each occurrence, is independently selected from H, C 1 -C 6 alkyl, benzyl, phenethyl, (C 1 -C 6 alkyl)-C(═O)—, and (C 1 -C 6 alkyl)-S(═O) 2 —;
R 16 , at each occurrence, is independently selected from
H, OH, C 1 -C 6 alkyl, kenzyl, phenethyl,
(C 1 -C 6 alkyl)-C(═O)—, and (C 1 -C 6 alkyl)-S(═O) 2 —;
R 17 is H, C 1 -C 6 alkyl, C 2 -C 6 alkoxyalkyl,
aryl substituted by 0-4 R 17a , or
—CH 2 -aryl substituted by 0-4 R 17a ;
R 17a is, at each occurrence, H, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, OH, F, Cl, Br, I, CF 3 , OCF 3 , SCH 3 , S(O)CH 3 , SO 2 CH 3 , —NH 2 , —N(CH 3 ) 2 , or C 1 -C 4 haloalkyl;
R 18 is selected from
H, C 1 -C 6 alkyl, phenyl, benzyl, phenethyl,
(C 1 -C 6 alkyl)-C(═O)—, and (C 1 -C 6 alkyl)-S(═O) 2 —;
R 19 is selected from
H, OH, C 1 -C 6 alkyl, phenyl, benzyl, phenethyl,
(C 1 -C 6 alkyl)-C(═O)—, and (C 1 -C 6 alkyl)-S(═O) 2 —; and
provided, when R 13 is H,
then Z is C 4 -C 6 alkyl substituted with 1-3 R 12 ;
C 2 -C 4 alkenyl substituted with 1-3 R 12 ; or
C 2 -C 4 alkynyl substituted with 1-3 R 12 .
29 . A process according to claim 1 for preparing a compound, of Formula (Ia):
a stereoisomer, or a pharmaceutically acceptable salt thereof,
wherein:
R 3 is —(CHR 7 ), —R 4 ,
n is 0 or 1;
R 3a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, allyl, or 3-buten-1-yl;
R 4 is H, OH, OR 14a ,
C 1 -C 4 alkyl substituted with 0-2 R 4a ,
C 2 -C 4 alkenyl substituted with 0-2 R 4a ,
C 2 -C 4 alkynyl substituted with 0-1 R 4a ,
C 3 -C 6 carbocycle substituted with 0-3 R 4b ,
aryl substituted with 0-3 R 4b , or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 4b ;
R 4a , at each occurrence, is independently selected from H, F, Cl, Br, I, CF 3 ,
C 3 -C 6 carbocycle substituted with 0-3 R 4b ,
phenyl substituted with 0-3 R 4b , and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 4b ;
R 4b , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 5 is H, OR 14 ;
C 1 -C 4 alkyl substituted with 0-3 R 5b ;
C 2 -C 4 alkenyl substituted with 0-3 R 5b ; or
C 2 -C 4 alkynyl substituted with 0-3 R 5b ;
R 5a is H, methyl, ethyl, propyl, or butyl;
R 5b , at each occurrence, is independently selected from:
H, methyl, ethyl, propyl, butyl, CF 3 , OR 14 , Cl, F, Br, I, ═O;
C 3 -C 6 carbocycle substituted with 0-3 R 5c ;
phenyl substituted with 0-3 R 5c ; and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 5c ;
R 5c , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 6 is H;
R 7 is selected from H, F, CF 3 , methyl, and ethyl;
Ring B is
R 10 is H, C(═O)R 17 , C(═O)OR 17 ;
C 1 -C 4 alkyl optionally substituted with 0-1 R 10a ;
phenyl substituted with 0-4 R 10b ;
C 3 -C 6 carbocycle substituted with 0-3 R 10b ; or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 10b ;
R 10a is selected from H, C 1 -C 4 alkyl, OR 14 , Cl, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 , CF 3 , and phenyl substituted with 0-4 R 10b ;
R 10b , at each occurrence, is independently selected from H, OH, C 1 -C 4 alkyl, C 1 -C 3 alkoxy, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , and CF 3 ;
Z is C 1 -C 4 alkyl substituted with 1-3 R 12 ;
C 2 -C 4 alkenyl substituted with 1-3 R 12 ;
C 2 -C 4 alkynyl substituted with 1-3 R 12 ;
aryl substituted with 0-4 R 12b ;
C 3 -C 6 carbocycle substituted with 0-4 R 12b ; or
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 12b ;
R 12 , at each occurrence, is independently selected from
aryl substituted with 0-4 R 12b ;
C 3 -C 6 carbocycle substituted with 0-4 R 12b ; and
5 to 10 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 10 membered heterocycle is substituted with 0-3 R 12b ;
R 12b , at each occurrence, is independently selected from
H, OH, Cl, F, NR 15 R 16 1 CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 13 , at each occurrence, is independently selected from
H, OH, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, CH, F, I, CN, NO 2 , NR 16 , alkyl,
R 14 is, at each occurrence, H, phenyl, benzyl, C 1 -C 4 alkyl, or C 2 -C 4 alkoxyalkyl;
R 15 , at each occurrence, is independently selected from H, C 1 -C 4 alkyl benzyl, phenethyl, (C 1 -C 4 alkyl)-C(═O)—, and (C 1 -C 4 alkyl)-S(═O) 2 —;
R 16 , at each occurrence, is independently selected from
H, OH, C 1 -C 4 alkyl, benzyl, phenethyl,
(C 1 -C 4 alkyl)-C(═O)—, and (C 1 -C 4 alkyl)-S(═O) 2 —;
R 17 is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl,
ethoxyethyl,
phenyl substituted by 0-3 R 17a , or
—CH 2 -phenyl substituted by 0-3 R 17a ; and
R 17a , at each occurrence, is independently H, methyl, methoxy, —OH, F, Cl, CF 3 , or OCF 3 ;
and, provided, when R 13 is H,
then Z is butyl substituted with 1-3 R 12 ;
C 2 -C 4 alkenyl substituted with 1-3 R 12 ; or
C 2 -C 4 alkynyl substituted with 1-3 R 12 .
30 . A process according to claim 1 for preparing a compound of Formula (Ia),
a stereoisomer or pharmaceutically acceptable salt thereof wherein:
R 3 is —(CHR 7 ) n —R 4 ,
—(CR 7 R 7a ) n —S—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —O—(CR 7 R 7a ) m —R 4 , or
—(CR 7 R 7a ) n —N(R 7b )—(CR 7 R 7a ) m —R 4 ;
n is 0 or 1;
m is 0 or 1;
R 3a is H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, allyl, or 3-buten-1-yl;
R 4 is H, OH, OR 14a ,
C 1 -C 4 alkyl substituted with 0-2 R 4a ,
C 2 -C 4 alkenyl substituted with 0-2 R 4a ,
C 2 -C 4 alkynyl substituted with 0-1 R 4a ,
C 3 -C 6 carbocycle substituted with 0-3 R 4b ,
aryl substituted with 0-3 R 4b , or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 4b ;
R 4a , at each occurrence, is independently selected from H, F, Cl, Br, I, CF 3 ,
C 3 -C 6 carbocycle substituted with 0-3 R 4b ,
phenyl substituted with 0-3 R 4b , and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 4b ;
R 4b , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 5 is H, OR 14 ;
C 1 -C 4 alkyl substituted with 0-3 R 5b ;
C 2 -C 4 alkenyl substituted with 0-3 R 5b ; or
C 2 -C 4 alkynyl substituted with 0-3 R 5b ;
R 5a is H, methyl, ethyl, propyl, or butyl;
R 5b , at each occurrence, is independently selected from:
H, methyl, ethyl, propyl, butyl, CF 3 , OR 14 , Cl, F, Br, I, ═O;
C 3 -C 6 carbocycle substituted with 0-3 R 5c ;
phenyl substituted with 0-3 R 5c ; and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 5c ;
R 5c , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 6 is H;
R 7 , at each occurrence, is independently selected from H, F, CF 3 , methyl, and ethyl;
Ring B is
R 10 is H, C(═O)R 17 , C(═O)OR 17 ;
C 1 -C 4 alkyl optionally substituted with 0-1 R 10a ;
phenyl substituted with 0-4 R 10b ;
C 3 -C 6 carbocycle substituted with 0-3 R 10b ; or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 10b ;
R 10a , at each occurrence, is independently selected from H, C 1 -C 4 alkyl, OR 14 , Cl, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 , CF 3 , and phenyl substituted with 0-4 R 10b ;
R 10b , at each occurrence, is independently selected from H, OH, C 1 -C 4 alkyl, C 1 -C 3 alkoxy, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , and CF 3 ;
Z is H;
C 1 -C 4 alkyl substituted with 0-3 R 12a ;
C 2 -C 4 alkenyl substituted with 0-3 R 12a ; or
C 2 -C 4 alkynyl substituted with 0-3 R 12a ;
R 12a , at each occurrence, is independently selected from
H, OH, Cl, F, NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 13 , at each occurrence, is independently selected from
H, OH, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , and CF 3 ;
R 14 is, at each occurrence, H, phenyl, benzyl, C 1 -C 4 alkyl, or C 2 -C 4 alkoxyalkyl;
R 14a is H, phenyl, benzyl, methyl ethyl, propyl or butyl;
R 15 , at each occurrence, is independently selected from H, C 1 -C 4 alkyl, benzyl, phenethyl, (C 1 -C 4 alkyl)-C(═O)—, and (C 1 -C 4 alkyl)-S(═O) 2 —;
R 16 , at each occurrence, is independently selected from
H, OH, C 1 -C 4 alkyl, benzyl, phenethyl,
(C 1 -C 4 alkyl)-C(═O)—, and (C 1 -C 4 alkyl)-S(═O) 2 —;
R 17 is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, phenyl substituted by 0-3 R 17a , or —CH 2 -phenyl substituted by 0-3 R 17a ; and
R 17a is, at each occurrence, selected independently from H, methyl, methoxy, —OH, F, Cl, CF 3 , and OCF 3 .
31 . A process according to claim 1 to prepare a compound of Formula (Ib),
a stereoisomer, or a pharmaceutically acceptable salt thereof wherein:
R 3 is —(CHR 7 ) n —R 4 ,
—(CR 7 R 7a ) n —S—(CR 7 R 7a ) m —R 4 ,
—(CR 7 R 7a ) n —O—(CR 7 R 7a ) m —R 4 , or
—(CR 7 R 7a ) n —N(R 7b )—(CR 7 R 7a ) m —R 4 ;
n is 0 or 1;
m is 0 or 1;
R 4 is H, OH, OR 14a ,
C 1 -C 4 alkyl substituted with 0-2 R 4a ,
C 2 -C 4 alkenyl substituted with 0-2 R 4a ,
C 2 -C 4 alkynyl substituted with 0-1 R 4a ,
C 3 -C 6 carbocycle substituted with 0-3 R 4b ,
aryl substituted with 0-3 R 4b , or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 4b ;
R 4a , at each occurrence, is independently selected from H, F, Cl, Br, I, CF 3 ,
C 3 -C 6 carbocycle substituted with 0-3 R 4b ,
phenyl substituted with 0-3 R 4b , and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 4b ;
R 4b , at each occurrence, is independently selected from H, OH, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 5 is H, OR 14 ;
C 1 -C 4 alkyl substituted with 0-3 R 5b ;
C 2 -C 4 alkenyl substituted with 0-3 R 5b ; or
C 2 -C 4 alkynyl substituted with 0-3 R 5b ;
R 5b , at each occurrence, is independently selected from:
H, methyl, ethyl, propyl, butyl, CF 3 , OR 14 , Cl, F, Br, I, ═O;
C 3 -C 6 carbocycle substituted with 0-3 R 5c ;
phenyl substituted with 0-3 R 5c ; and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with
R 5c , at each occurrence, is independently selected from H, OH, Cl, F. Br, I, CN, NO 2 , NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 6 is H;
R 7 , at each occurrence, is independently selected from H, F, CF 3 , methyl, and ethyl;
R 7a , at each occurrence, is independently selected from H, OH, Cl, F, Br, T, CN, NO 2 , CF 3 , and
C 1 -C 4 alkyl;
R 7b is selected from H and C 1 -C 4 alkyl;
Ring B is
R 10 is H, C(═O)R 17 , C(═O)OR 17 ;
C 1 -C 4 alkyl optionally substituted with 0-1 R 10a ;
phenyl substituted with 0-4 R 10b ;
C 3 -C 6 carbocycle substituted with 0-3 R 10b ; or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 10b ;
R 10a is selected from H, C 1 -C 4 alkyl, OR 14 , Cl, F, Br, I, ═O, CN, NO 2 , NR 15 R 16 , CF 3 , and phenyl substituted with 0-4 R 10b ;
R 10b , at each occurrence, is independently selected from H, OH, C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C, F, Br, I, CN, NO 2 , NR 15 R 16 , and CF 3 ;
Z is H;
C 1 -C 4 alkyl substituted with 0-3 R 12a ;
C 2 -C 4 alkenyl substituted with 0-3 R 12a ; or
C 2 -C 4 alkynyl substituted with 0-3 R 12a ;
R 12a , at each occurrence, is independently selected from
H, OH, Cl, F, NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , C 1 -C 4 alkyl, C 1 -C 3 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 13 , at each occurrence, is independently selected from
H, OH, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, Cl, F, Br, I, CN, NO 2 , NR 15 R 16 , and CF 3 ;
R 14 is H, phenyl, benzyl, C 1 -C 4 alkyl, or C 2 -C 4 alkoxyalkyl;
R 15 , at each occurrence, is independently selected from H, C 1 -C 4 alkyl, benzyl, phenethyl, (C 1 -C 4 alkyl)-C(═O)—, and (C 1 -C 4 alkyl)-S(═O) 2 —;
R 16 , at each occurrence, is independently selected from
H, OH, C 1 -C 4 alkyl, benzyl, phenethyl,
(C 1 -C 4 alkyl)-C(═O)—, and (C 1 -C 4 alkyl)-S(═O) 2 —;
R 17 is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl,
phenyl substituted by 0-3 R 17a , or
—CH 2 -phenyl substituted by 0-3 R 17a ;
R 17a , at each occurrence, is independently selected from H, methyl, methoxy, —OH, F, Cl, CF 3 , and OCF 3 .
32 . A process according to claim 1 to prepare a compound of Formula (Ie):
a stereoisomer, or a pharmaceutically acceptable salt thereof wherein:
R 3 is R 4 ,
R 4 is C 1 -C 4 alkyl substituted with 0-1 R 4a ,
C 2 -C 4 alkenyl substituted with 0-1 R 4a , or
C 2 -C 4 alkynyl substituted with 0-1 R 4a ;
R 4a is selected from
H, F, CF 3 ,
C 3 -C 6 carbocycle substituted with 0-3 R 4b , phenyl substituted with 0-3 R 4b , and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 4b ; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
R 4b , at each occurrence, is independently selected from H, OH, Cl, F, NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 5 is C 1 -C 4 alkyl substituted with 0-1 R 5b ;
C 2 -C 4 alkenyl substituted with 0-1 R 5b ; or
C 2 -C 4 alkynyl substituted with 0-1 R 5b ;
R 5b is selected from:
H, methyl, ethyl, propyl, butyl, CF 3 , OR 14 , ═O;
C 3 -C 6 carbocycle substituted with 0-2 R 5c ;
phenyl substituted with 0-3 R 5c ; and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 5c : wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
R 5c , at each occurrence, is independently selected from H, OH, Cl, F, NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 10 is H, C(═O)R 17 , C(—O)OR 17 ;
C 1 -C 4 alkyl optionally substituted with 0-1 R 10a ;
phenyl substituted with 0-4 R 10b ;
C 3 -C 6 carbocycle substituted with 0-3 R 10b ; or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 10b ; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
R 10a is selected from H, methyl, ethyl, propyl, butyl, OR 14 , Cl, F, ═O, NR 15 R 16 , CF 3 , and phenyl substituted with 0-4 R 10b ;
R 10b , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl, F, NR 15 R 16 , and CF 3 ;
Z is C 1 -C 3 alkyl substituted with 1-3 R 12 ;
C 2 -C 3 alkenyl substituted with 1-3 R 2 ;
C 2 -C 3 , alkynyl substituted with 1-3 R 12 ;
aryl substituted with 0-4 R 12b ;
C 3 -C 6 carbocycle substituted with 0-3 R 12b , or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 12b ; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
R 12 , at each occurrence, is independently selected from
aryl substituted with 0-4 R 12b ;
C 3 -C 6 carbocycle substituted with 0-3 R 12b ; and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 12 b; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
R 12b , at each occurrence, is independently selected from
H, OH, Cl, F, NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 13 , at each occurrence, is independently selected from
H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, NR 15 R 16 , and CFW;
R 14 is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
R 15 , at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
R 16 , at each occurrence, is independently selected from
H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(═O)—, ethyl-C(═O)—, methyl-S(═O) 2 —, and ethyl-S(═O) 2 —;
R 17 is H, methyl, ethyl, propyl, butyl, methoxymethyl,
ethoxymethyl, methoxyethyl, ethoxyethyl,
phenyl substituted by 0-3 R 17a , or
—CH 2 -phenyl substituted by 0-3 R 17a ; and
R 17a , at each occurrence, is H, methyl, methoxy, —OH, F, Cl, CF 3 , or OCF 3 ; and
provided, when R 13 is H,
then Z is C 2 -C 3 alkenyl substituted with 1-3 R 12 ; or
C 2 -C 3 alkynyl substituted with 1-3 R 12 .
33 . A process according to claim 32 to prepare a compound of Formula (Ie):
a stereoisomer or a pharmaceutically acceptable salt thereof wherein:
R 3 is R 4 ,
R 4 is C 1 -C 4 alkyl substituted with 0-1 R 4a ,
C 2 -C 4 alkenyl substituted with 0-1 R 4a , or
C 2 -C 4 alkynyl substituted with 0-1 R 4a ;
R 4a is selected from
H, F, CF 3 ,
C 3 -C 6 carbocycle substituted with 0-3 R 4b , phenyl substituted with 0-3 R 4b , and 5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 4b ; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
R 4b , at each occurrence, is independently selected from H, OH, Cl, F, NR 15 R 16 . CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 5 is C 1 -C 4 alkyl substituted with 0-1 R 5b ;
C 2 -C 4 alkenyl substituted with 0-1 R 5b ; or
C 2 -C 4 alkynyl substituted with 0-1 R 5b ;
R 5b is selected from:
H, methyl, ethyl, propyl, butyl, CF 3 , OR 14 , ═O;
C 3 -C 6 carbocycle substituted with 0-2 R 5c ;
phenyl substituted with 0-3 R 5c ; and
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 5c ; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
R 5c , at each occurrence, is independently selected from H, OH, Cl, F, NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(O) 2 CH 3 , methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 10 is H C(═O)R 17 , C(═O)OR 17 ;
C 1 -C 4 alkyl optionally substituted with 0-1 R 10a ;
phenyl substituted with 0-4 R 10b ;
C 3 -C 6 carbocycle substituted with 0o3 R 10b , or
5 to 6 membered heterocycle containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulphur, wherein said 5 to 6 membered heterocycle is substituted with 0-3 R 10b ; wherein said 5 to 6 membered heterocycle is selected from pyridinyl, pyrimidinyl, triazinyl, furanyl, thienyl, thiazolyl, pyrrolyl, piperazinyl, piperidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, and tetrazolyl;
R 10a is selected from H, methyl, ethyl, propyl, butyl, OR 14 , Cl, F, ═O, NR 15 R 16 , CF 3 , and phenyl substituted with 0-4 R 10b ;
R 10b , at each occurrence, is independently selected from H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, Cl, F, NR 15 R 16 , and CF 3 :
Z is H;
C 1 -C 4 alkyl substituted with 0-3 R 12a ;
C 2 -C 4 alkenyl substituted with Q-3 R 12a ; or
C 2 -C 4 alkynyl substituted with 0-3 R 12a ;
R 12a , at each occurrence, is independently selected from
H, OH, Cl, F. NR 15 R 16 , CF 3 , acetyl, SCH 3 , S(═O)CH 3 , S(═O) 2 CH 3 , methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy;
R 13 , at each occurrence, is independently selected from
H, OH, methyl, ethyl, propyl, butyl, methoxy, ethoxy, Cl, F, Br, CN, NR 15 R 16 , and CF 3 ;
R 14 is H, phenyl, benzyl, methyl, ethyl, propyl, or butyl;
R 15 , at each occurrence, is independently selected from H, methyl, ethyl, propyl, and butyl;
R 16 , at each occurrence, is independently selected from
H, OH, methyl, ethyl, propyl, butyl, benzyl, phenethyl, methyl-C(═O)—, ethyl-C(═O)—, methyl-S(═O) 2 —, and ethyl-S(═O) 2 —;
R 17 is H, methyl, ethyl, propyl, butyl, methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl,
phenyl substituted by 0-3 R 17a , or
—CH 2 -phenyl substituted by 0-3 R 17a ; and
R 17a , at each occurrence, is independently selected from H, methyl, methoxy, —OH, F, Cl, CF 3 , and OCF 3 .
34 . A process according to claim 32 , for preparing a compound of Formula (Ie)
a stereoisomer, or pharmaceutically acceptable salt thereof, wherein:
R 3 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 (CH 3 ) 2 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH 2 CH 2 CH═CH 2 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), —C≡CH, —CH 2 C≡CH, —CH 2 C≡C(CH 3 ), cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, (2-Cl-phenyl)CH 2 —, (3-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 —, (2,3-diF-phenyl)CH 2 —, (2,4-diF-phenyl)CH 2 —, (2,5-diF-phenyl)CH 2 —, (2,6-diF-phenyl)CH 2 —, (3,4-diF-phenyl)CH 2 —, (3,5-diF-phenyl)CH 2 —, (2,3-diCl-phenyl)CH 2 —, (2,4-diCl-phenyl)CH 2 —, (2,5-diCl-phenyl)CH 2 —, (2,6-diCl-phenyl)CH 2 —, (3,4-diCl-phenyl)CH 2 —, (3,5-diCl-phenyl)CH 2 —, (3-F-4-Cl-phenyl)CH 2 —, (3-F-5-Cl-phenyl)CH 2 —, (3-Cl-F-phenyl)CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, (2-Cl-phenyl)CH 2 CH 2 —, (3-Cl-phenyl)CH 2 CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, (2,3-diF-phenyl)CH 2 CH 2 —, (2,4-diF-phenyl)CH 2 CH 2 —, (2,5-diF-phenyl)CH 2 CH 2 —, (2,6-diF-phenyl)CH 2 CH 2 —, (3,4-diF-phenyl)CH 2 CH 2 —, (3,5-diF-phenyl)CH 2 CH 2 —, (2,3-diCl-phenyl)CH 2 CH 2 —, (2,4-diCl-phenyl)CH 2 CH 2 —, (2,5-diCl-phenyl)CH 2 CH 2 —, (2,6-diCl-phenyl)CH 2 CH 2 —, (3,4-diCl-phenyl)CH 2 CH 2 —, (3,5-diCl-phenyl)CH 2 CH 2 —, (3-F-4-Cl-phenyl)CH 2 CH 2 —, or (3-F-5-Cl-phenyl)CH 2 CH 2 —,
R 5 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 C(CH 3 ) 3 , —CH 2 CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 )CH 2 CH 3 , —CH 2 CH 2 CH(CH 3 ) 2 , —CH(CH 2 CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH═CHCH 3 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(C 6 H 5 ), —CH 2 CH═C(CH 3 ) 2 , cis-CH 2 CH═CHCH 2 CH 3 , trans-CH 2 CH═CHCH 2 CH 3 , cis-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CHCH 2 (C 6 H 5 ), —C≡CH, —CH 2 C≡CH, —CH 2 C≡C(CH 3 ), —CH 2 C≡C(C 6 H 5 ) —CH 2 CH 2 C≡CH, —CH 2 CH 2 C≡C(CH 3 ), —CH 2 CH 2 C≡C(C 6 H 5 ) cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, (2-CH 3 -cyclopropyl)CH 2 —, (3-CH 3 -cyclobutyl)CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, cyclohexyl-CH 2 CH 2 —, (2-CH 3 -cyclopropyl)CH 2 CH 2 —, (3-CH 3 -cyclobutyl)CH 2 CH 2 —, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, furanyl-CH 2 —, thienyl-CH 2 —, pyridyl-CH 2 —, 1-imidazolyl-CH 2 —, oxazolyl-CH 2 —, isoxazolyl-CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, furanyl-CH 2 CH 2 —, thienyl-CH 2 CH 2 —, pyridyl-CH 2 CH 2 —, 1-imidazolyl-CH 2 CH 2 —, oxazolyl-CH 2 CH 2 —, or isoxazolyl-CH 2 CH 2 —,
Z is phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl, 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl, 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl, 2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl, 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl, 3-Cl-F-phenyl, 2-MeO-phenyl, 3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl, 2-CF 3 O-phenyl, 3-CF 3 O-phenyl, 4-CF 3 O-phenyl, furanyl, thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl, 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, (2-Cl-phenyl)CH 2 —, (3-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 —, (2,3-diF-phenyl)CH 2 —, (2,4-diF-phenyl)CH 2 —, (2,5-diF-phenyl)CH 2 —, (2,6-diF-phenyl)CH 2 —, (3,4-diF-phenyl)CH 2 —, (3,5-diF-phenyl)CH 2 —, (2,3-diCl-phenyl)CH 2 —, (2,4-diCl-phenyl)CH 2 —, (2,5-diCl-phenyl)CH 2 —, (2,6-diCl-phenyl)CH 2 —, (3,4-diCl-phenyl)CH 2 —, (3,5-diCl-phenyl)CH 2 —, (3-F-4-Cl-phenyl)CH 2 —, (3-F-5-Cl-phenyl)CH 2 —, (3-Cl-F-phenyl)CH 2 —, (2-MeO-phenyl)CH 2 —, (3-MeO-phenyl)CH 2 —, (4-MeO-phenyl)CH 2 —, (2-Me-phenyl)CH 2 —, (3-Me-phenyl)CH 2 —, (4-Me-phenyl)CH 2 —, (2-MeS-phenyl)CH 2 —, (3-MeS-phenyl)CH 2 —, 4-MeS-phenyl)CH 2 —, (2-CF 3 O-phenyl)CH 2 —, (3-CF 3 O-phenyl)CH 2 —, (4-CF 3 O-phenyl)CH 2 —, (furanyl)CH 2 —,(thienyl)CH 2 —, (pyridyl)CH 2 —, (2-Me-pyridyl)CH 2 —, (3-Me-pyridyl)CH 2 —, (4-Me-pyridyl)CH 2 —, (1-imidazolyl)CH 2 —, (oxazolyl)CH 2 —, (isoxazolyl)CH 2 —, (cyclopropyl)CH 2 —, (cyclobutyl)CH 2 —, (cyclopentyl)CH 2 —, (cyclohexyl)CH 2 —, phenyl-CH 2 CH 2 —, (phenyl) 2 CHCH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, (2-Cl-phenyl)CH 2 CH 2 —, (3-Cl-phenyl)CH 2 CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, (2,3-diF-phenyl)CH 2 CH 2 —, (2,4-diF-phenyl)CH 2 CH 2 —, (2,5-diF-phenyl)CH 2 CH 2 —, (2,6-diF-phenyl)CH 2 CH 2 —, (3,4-diF-phenyl)CH 2 CH 2 —, (3,5-diF-phenyl)CH 2 CH 2 —, (2,3-diCl-phenyl)CH 2 CH 2 —, (2,4-diCl-phenyl)CH 2 CH 2 —, (2,5-diCl-phenyl)CH 2 CH 2 —, (2,6-diCl-phenyl)CH 2 CH 2 —, (3,4-diCl-phenyl)CH 2 CH 2 —, (3,5-diCl-phenyl)CH 2 CH 2 —, (3-F-4-Cl-phenyl)CH 2 CH 2 —, (3-F-5-Cl-phenyl)CH 2 CH 2 —, (3-Cl-F-phenyl)CH 2 CH 2 —, (2-MeO-phenyl)CH 2 CH 2 —, (3-MeO-phenyl)CH 2 CH 2 —, (4-MeO-phenyl)CH 2 CH 2 —, (2-Me-phenyl)CH 2 CH 2 —, (3-Me-phenyl)CH 2 CH 2 —, (4-Me-phenyl)CH 2 CH 2 —, (2-MeS-phenyl)CH 2 CH 2 —, (3-MeS-phenyl)CH 2 CH 2 —, (4-MeS-phenyl)CH 2 CH 2 —, (2-CF 3 O-phenyl)CH 2 CH 2 —, (3-CF 3 O-phenyl)CH 2 CH 2 —, (4-CF 3 O-phenyl)CH 2 CH 2 —, (furanyl)CH 2 CH 2 —, (thienyl)CH 2 CH 2 —, (pyridyl)CH 2 CH 2 —, (2-Me-pyridyl)CH 2 CH 2 —, (3-Me-pyridyl)CH 2 CH 2 —, (4-Me-pyridyl)CH 2 CH 2 —, (imidazolyl)CH 2 CH 2 —, (oxazolyl)CH 2 CH 2 —, (isoxazolyl)CH 2 CH 2 -t (cyclopropyl)CH 2 CH 2 —, (cyclobutyl)CH 2 CH 2 —, (cyclopentyl)CH 2 CH 2 —, or (cyclohexyl)CH 2 CH 2 ;
R 10 is H, methyl, ethyl, phenyl, benzyl, phenethyl, 4-F-phenyl, (4-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 CH 2 —, 4-Cl-phenyl, (4-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, 4-CH 3 -phenyl, (4-CH 3 -phenyl)CH 2 -t (4-CH 3 -phenyl)CH 2 CH 2 —, 4-CF 3 -phenyl, (4-CF 3 -phenyl)CH 2 —, or (4-CF 3 -phenyl)CH 2 CH 2 —; and
R 13 , at each occurrence, is independently selected from
H, F, Cl, OH, —CH 3 , —CH 2 CH 3 , —OCH 3 , and —CF 3 .
35 . A process according to claim 32 for preparing a compound of Formula (Ie)
a stereoisomer, or pharmaceutically acceptable salt thereof, wherein:
R 3 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 (CH 3 ) 2 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH 2 CH 2 CH═CH 2 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), —C≡CH, —CH 2 C≡CH, —CH 2 C═C(CH 3 ), cyclopropyl-CH 2 -r cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, (2-Cl-phenyl)CH 2 —, (3-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 —, (2,3-diF-phenyl)CH 2 —, (2,4-diF-phenyl)CH 2 —, (2,5-diF-phenyl)CH 2 —, (2,6-diF-phenyl)CH 2 —, (3,4-diF-phenyl)CH 2 —, (3,5-diF-phenyl)CH 2 —, (2,3-diCl-phenyl)CH 2 —, (2,4-diCl-phenyl)CH 2 —, (2,5-diCl-phenyl)CH 2 —, (2,6-diCl-phenyl)CH 2 —, (3,4-diCl-phenyl)CH 2 —, (3,5-diCl-phenyl)CH 2 —, (3-F-4-Cl-phenyl)CH 2 —, (3-F-5-Cl-phenyl)CH 2 —, (3-Cl-F-phenyl)CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, (2-Cl-phenyl)CH 2 CH 2 —, (3-Cl-phenyl)CH 2 CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, (2,3-diF-phenyl)CH 2 CH 2 —, (2,4-diF-phenyl)CH 2 CH 2 —, (2,5-diF-phenyl)CH 2 CH 2 —, (2,6-diF-phenyl)CH 2 CH 2 —, (3,4-diF-phenyl)CH 2 CH 2 —, (3,5-diF-phenyl)CH 2 CH 2 —, (2,3-diCl-phenyl)CH 2 CH 2 —, (2,4-diCl-phenyl)CH 2 CH 2 —, (2,5-diCl-phenyl)CH 2 CH 2 —, (2,6-diCl-phenyl)CH 2 CH 2 —, (3,4-diCl-phenyl)CH 2 CH 2 —, (3,5-diCl-phenyl)CH 2 CH 2 —, (3-F-4-Cl-phenyl)CH 2 CH 2 —, or (3-F-5-Cl-phenyl)CH 2 CH 2 —,
R 5 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 C2CH 2 CH 3 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 C(CH 3 ) 3 , —CH 2 CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 )CH 2 CH 3 , —CH 2 CH 2 CH(CH 3 ) 2 , —CH(CH 2 CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH═CHCH 3 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(C 6 H 5 ), —CH 2 CH═C(CH 3 ) 2 , cis-CH 2 CH═CHCH 2 CH 3 , trans-CH 2 CH═CHCH 2 CH 3 , cis-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CHCH 2 (C 6 H 5 ), —C≡CH, —CH 2 C≡CH, —CH 2 C≡C(CH 3 ), —CH 2 C≡C(C 6 H 5 ) —CH 2 CH 2 C≡CH, —CH 2 CH 2 C≡C(CH 3 ), —CH 2 CH 2 C≡C(C 6 H 5 ) cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, (2-CH 3 -cyclopropyl)CH 2 —, (3-CH 3 -cyclobutyl)CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, cyclohexyl-CH 2 CH 2 —, (2-CH 3 -cyclopropyl)CH 2 CH 2 —, (3-CH 3 -cyclobutyl)CH 2 CH 2 —, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, furanyl-CH 2 —, thienyl-CH 2 —, pyridyl-CH 2 —, 1-imidazolyl-CH 2 —, oxazolyl-CH 2 —, isoxazolyl-CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, furanyl-CH 2 CH 2 —, thienyl-CH 2 CH 2 —, pyridyl-CH 2 CH 2 —, 1-imidazolyl-CH 2 CH 2 —, oxazolyl-CH 2 CH 2 —, or isoxazolyl-CH 2 CH 2
Z is phenyl, 2-F-phenyl, 3-F-phenyl, 4-F-phenyl, 2-Cl-phenyl, 3-Cl-phenyl, 4-Cl-phenyl, 2,3-diF-phenyl, 2,4-diF-phenyl, 2,5-diF-phenyl, 2,6-diF-phenyl, 3,4-diF-phenyl, 3,5-diF-phenyl, 2,3-diCl-phenyl, 2,4-diCl-phenyl, 2,5-diCl-phenyl, 2,6-diCl-phenyl, 3,4-diCl-phenyl, 3,5-diCl-phenyl, 3-F-4-Cl-phenyl, 3-F-5-Cl-phenyl, 3-Cl-F-phenyl, 2-MeO-phenyl, 3-MeO-phenyl, 4-MeO-phenyl, 2-Me-phenyl, 3-Me-phenyl, 4-Me-phenyl, 2-MeS-phenyl, 3-MeS-phenyl, 4-MeS-phenyl, 2-CF 3 O-phenyl, 3-CF 3 O-phenyl, 4-CF 3 O-phenyl, furanyl, thienyl, pyridyl, 2-Me-pyridyl, 3-Me-pyridyl, 4-Me-pyridyl, 1-imidazolyl, oxazolyl, isoxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, (2-Cl-phenyl)CH 2 —, (3-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 —, (2,3-diF-phenyl)CH 2 —, (2,4-diF-phenyl)CH 2 —, (2,5-diF-phenyl)CH 2 —, (2,6-diF-phenyl)CH 2 —, (3,4-diF-phenyl)CH 2 —, (3,5-diF-phenyl)CH 2 —, (2,3-diCl-phenyl)CH 2 —, (2,4-diCl-phenyl)CH 2 —, (2,5-diCl-phenyl)CH 2 —, (2,6-diCl-phenyl)CH 2 —, (3,4-diCl-phenyl)CH 2 —, (3,5-diCl-phenyl)CH 2 —, (3-F-4-Cl-phenyl)CH 2 —, (3-F-5-Cl-phenyl)CH 2 —, (3-Cl-F-phenyl)CH 2 —, (2-MeO-phenyl)CH 2 —, (3-MeO-phenyl)CH 2 —, (4-MeO-phenyl)CH 2 —, (2-Me-phenyl)CH 2 —, (3-Me-phenyl)CH 2 —, (4-Me-phenyl)CH 2 —, (2-MeS-phenyl)CH 2 —, (3-MeS-phenyl)CH 2 —, 4-MeS-phenyl)CH 2 —, (2-CF 3 O-phenyl)CH 2 —, (3-CF 3 O-phenyl)CH 2 —, (4-CF 3 O-phenyl)CH 2 —, (furanyl)CH 2 —,(thienyl)CH 2 —, (pyridyl)CH 2 —, (2-Me-pyridyl)CH 2 —, (3-Me-pyridyl)CH 2 —, (4-Me-pyridyl)CH 2 —, (1-imidazolyl)CH 2 —, (oxazolyl)CH 2 —, (isoxazolyl)CH 2 —, (cyclopropyl)CH 2 —, (cyclobutyl)CH 2 —, (cyclopentyl)CH 2 —, (cyclohexyl)CH 2 —, phenyl-CH 2 CH 2 —, (phenyl) 2 CHCH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, (2-Cl-phenyl)CH 2 CH 2 —, (3-Cl-phenyl)CH 2 CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, (2,3-diF-phenyl)CH 2 CH 2 —, (2,4-diF-phenyl)CH 2 CH 2 —, (2,5-diF-phenyl)CH 2 CH 2 —, (2,6-diF-phenyl)CH 2 CH 2 —, (3,4-diF-phenyl)CH 2 CH 2 —, (3,5-diF-phenyl)CH 2 CH 2 —, (2,3-diCl-phenyl)CH 2 CH 2 —, (2,4-diCl-phenyl)CH 2 CH 2 —, (2,5-diCl-phenyl)CH 2 CH 2 —, (2,6-diCl-phenyl)CH 2 CH 2 —, (3,4-diCl-phenyl)CH 2 CH 2 —, (3,5-diCl-phenyl)CH 2 CH 2 —, (3-F-4-Cl-phenyl)CH 2 CH 2 —, (3-F-5-Cl-phenyl)CH 2 CH 2 —, (3-Cl-F-phenyl)CH 2 CH 2 —, (2-MeO-phenyl)CH 2 CH 2 —, (3-MeO-phenyl)CH 2 CH 2 —, (4-MeO-phenyl)CH 2 CH 2 —, (2-Me-phenyl)CH 2 CH 2 —, (3-Me-phenyl)CH 2 CH 2 —, (4-Me-phenyl)CH 2 CH 2 —, (2-MeS-phenyl)CH 2 CH 2 —, (3-MeS-phenyl)CH 2 CH 2 —, (4-MeS-phenyl)CH 2 CH 2 —, (2-CF 3 O-phenyl)CH 2 CH 2 —, (3-CF 3 O-phenyl)CH 2 CH 2 —, (4-CF 3 O-phenyl)CH 2 CH 2 —, (furanyl)CH 2 CH 2 —,(thienyl)CH 2 CH 2 —, (pyridyl)CH 2 CH 2 —, (2-Me-pyridyl)CH 2 CH 2 —, (3-Me-pyridyl)CH 2 CH 2 —, (4-Me-pyridyl)CH 2 CH 2 —, (imidazolyl)CH 2 CH 2 —, (oxazolyl)CH 2 CH 2 —, (isoxazolyl)CH 2 CH 2 -(cyclopropyl)CH 2 CH 2 —, (cyclobutyl)CH 2 CH 2 , (cyclopentyl)CH 2 CH 2 —, or (cyclohexyl)CH 2 CH 2 ;
R 10 is H, methyl, ethyl, phenyl, benzyl, phenethyl, 4-F-phenyl, (4-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 CH 2 —, 4-Cl-phenyl, (4-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, 4-CH 3 -phenyl, (4-CH 3 -phenyl)CH 2 —, (4-CH 3 -phenyl)CH 2 CH 2 —, 4-CF 3 -phenyl, (4-CF 3 -phenyl)CH 2 —, or (4-CF 3 -phenyl)CH 2 CH 2 —; and
R 13 , at each occurrence, is independently selected from
H, F, Cl, OH, —CH 3 , —CH 2 CH 3 , —OCH 3 , and —CF 3 .
36 . A process according to claim 32 for preparing a compound of Formula (Ie)
a stereoisomer, or pharmaceutically acceptable salt thereof, wherein:
R 3 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 (CH 3 ) 2 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH 2 CH 2 CH═CH 2 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), —C≡CH, —CH 2 C≡CH, —CH 2 C≡C(CH 3 ), cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, cyclohexyl-CH 2 CH 2 —, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, (2-Cl-phenyl)CH 2 —, (3-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 —, (2,3-diF-phenyl)CH 2 —, (2,4-diF-phenyl)CH 2 —, (2,5-diF-phenyl)CH 2 —, (2,6-diF-phenyl)CH 2 —, (3,4-diF-phenyl)CH 2 —, (3,5-diF-phenyl)CH 2 —, (2,3-diCl-phenyl)CH 2 —, (2,4-diCl-phenyl)CH 2 —, (2,5-diCl-phenyl)CH 2 —, (2,6-diCl-phenyl)CH 2 —, (3,4-diCl-phenyl)CH 2 —, (3,5-diCl-phenyl)CH 2 —, (3-F-4-Cl-phenyl)CH 2 —, (3-F-5-Cl-phenyl)CH 2 —, (3-Cl-F-phenyl)CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, (2-Cl-phenyl)CH 2 CH 2 —, (3-Cl-phenyl)CH 2 CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, (2,3-diF-phenyl)CH 2 CH 2 —, (2,4-diF-phenyl)CH 2 CH 2 —, (2,5-diF-phenyl)CH 2 CH 2 —, (2,6-diF-phenyl)CH 2 CH 2 —, (3,4-diF-phenyl)CH 2 CH 2 —, (3,5-diF-phenyl)CH 2 CH 2 —, (2,3-diCl-phenyl CH 2 CH 2 —, (2,4-diCl-phenyl, CH 2 CH 2 —, (2,5-diCl-phenyl)CH 2 CH 2 —, (2,6-diCl-phenyl)CH 2 CH 2 —, (3,4-diCl-phenyl)CH 2 CH 2 —, (3,5-diCl-phenyl)CH 2 CH 2 —, (3-F-4-Cl-phenyl)CH 2 CH 2 —, or (3-F-5-Cl-phenyl)CH 2 CH 2 —,
R 5 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 C(CH 3 ) 3 , —CH 2 CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 )CH 2 CH 3 , —CH 2 CH 2 CH(CH 3 ) 2 , —CH(CH 2 CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH═CHCH 3 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(C 6 H 5 ), —CH 2 CH═C(CH 3 ) 2 , cis-CH 2 CH═CHCH 2 CH 3 , trans-CH 2 CH═CHCH 2 CH 3 , cis-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CHCH 2 (C 6 H 5 ), —C≡CH, —CH 2 C═CH, —CH 2 C≡C(CH 3 ), —CH 2 C≡C(C 6 H 5 ) —CH 2 CH 2 C≡CH, —CH 2 CH 2 C═C(CH 3 ), —CH 2 CH 2 C≡C(C 6 H 5 ), cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, (2-CH 3 -cyclopropyl)CH 2 —, (3-CH 3 -cyclobutyl) CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, cyclohexyl-CH 2 CH 2 —, (2-CH 3 -cyclopropyl)CH 2 CH 2 —, (3-CH 3 -cyclobutyl)CH 2 CH 2 —, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, furanyl-CH 2 —, thienyl-CH 2 —, pyridyl-CH 2 —, 1-imidazolyl-CH 2 —, oxazolyl-CH 2 —, isoxazolyl-CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, furanyl-CH 2 CH 2 —, thienyl-CH 2 CH 2 —, pyridyl-CH 2 CH 2 —, 1-imidazolyl-CH 2 CH 2 —, oxazolyl-CH 2 CH 2 —, or isoxazolyl-CH 2 CH 2 —,
Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, s-butyl, t-butyl, or allyl;
R 10 is H, methyl, ethyl, phenyl, benzyl, phenethyl, 4-F-phenyl, (4-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 CH 2 —, 4-Cl-phenyl, (4-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, 4-CH 3 -phenyl, (4-CH 3 -phenyl)CH 2 —, (4-CH 3 -phenyl)CH 2 CH 2 —, 4-CF 3 -phenyl, (4-CF 3 -phenyl)CH 2 —, or (4-CF 3 -phenyl)CH 2 CH 2 —; and
R 13 , at each occurrence, is independently selected from H, F, Cl, OH, —CH 3 , —CH 2 CH 3 , —OCH 3 , and —CF 3 .
37 . A process according to claim 32 for preparing a compound of Formula (H)
a stereoisomer, or pharmaceutically acceptable salt thereof, wherein:
R 3 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 (CH 3 ) 2 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH 2 CH 2 CH═CH 2 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), —C≡CH, —CH 2 C≡CH, —CH 2 C≡C(CH 3 ), cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, cyclohexyl-CH 2 CH 2 —, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, (2-Cl-phenyl)CH 2 —, (3-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 —, (2,3-diF-phenyl, CH 2 —, (2,4-diF-phenyl)CH 2 —, (2,5-diF-phenyl)CH 2 —, (2,6-diF-phenyl)CH 2 —, (3,4-diF-phenyl)CH 2 —, (3,5-diF-phenyl)CH 2 —, (2,3-diCl-phenyl)CH 2 —, (2,4-diCl-phenyl)CH 2 —, (2,5-diCl-phenyl)CH 2 —, (2,6-diCl-phenyl)CH 2 —, (3,4-diCl-phenyl)CH 2 —, (3,5-diCl-phenyl)CH 2 —, (3-F-4-Cl-phenyl)CH 2 —, (3-F-5-Cl-phenyl)CH 2 —, (3-Cl-F-phenyl)CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, (2-Cl-phenyl)CH 2 CH 2 —, (3-Cl-phenyl)CH 2 CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, (2,3-diF-phenyl)CH 2 CH 2 —, (2,4-diF-phenyl)CH 2 CH 2 —, (2,5-diF-phenyl)CH 2 CH 2 —, (2,6-diF-phenyl)CH 2 CH 2 —, (3,4-diF-phenyl)CH 2 CH 2 —, (3,5-diF-phenyl)CH 2 CH 2 —, (2,3-diCl-phenyl)CH 2 CH 2 —, (2,4-diCl-phenyl)CH 2 CH 2 —, (2,5-diCl-phenyl)CH 2 CH 2 —, (2,6-diCl-phenyl)CH 2 CH 2 —, (3,4-diCl-phenyl)CH 2 CH 2 —, (3,5-diCl-phenyl)CH 2 CH 2 —, (3-F-4-C 1 -phenyl)CH 2 CH 2 —, or (3-F-5-Cl-phenyl)CH 2 CH 2 —,
R 5 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH(CH 3 ) 2 , —CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 C(CH 3 ) 3 , —CH 2 CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 )CH 2 CH 3 , —CH 2 CH 2 CH(CH 3 ) 2 , —CH(CH 2 CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 r —CH 2 CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH═CHCH 3 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(C 6 H 5 ), —CH 2 CH═C(CH 3 ) 2 , cis-CH 2 CH═CHCH 2 CH 3 , trans-CH 2 CH═CHCH 2 CH 3 , cis-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH 2 CH—CH(CH 3 ), trans-CH 2 CH═CHCH 2 (C 6 H 5 ), —C≡CH, —CH 2 C≡CH, —CH 2 C≡C(CH 3 ), —CH 2 C≡C(C 6 H 5 ) —CH 2 CH 2 C≡CH, —CH 2 CH 2 C≡C(CH 3 ), —CH 2 CH 2 C≡C(C 6 H 5 ), cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, (2-CH 3 -cyclopropyl)CH 2 —, (3-CH 3 -cyclobutyl) CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, cyclohexyl-CH 2 CH 2 —, (2-CH 3 -cyclopropyl)CH 2 CH 2 —, (3-CH 3 -cyclobutyl)CH 2 CH 2 —, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, furanyl-CH 2 —, thienyl-CH 2 —, pyridyl-CH 2 —, 1-imidazolyl-CH 2 —, oxazolyl-CH 2-1 isoxazolyl-CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, furanyl-CH 2 CH 2 —, thienyl-CH 2 CH 2 —, pyridyl-CH 2 CH 2 —, 1-imidazolyl-CH 2 CH 2 — oxazolyl-CH 2 CH 2 —, or isoxazolyl-CH 2 CH 2 —,
Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, s-butyl, t-butyl, or allyl; and
R 13 , at each occurrence, is independently selected from H, F, Cl, OH, —CH 3 , —CH 2 CH 3 , —OCH 3 , and —CF 3 .
38 . A process according to claim 32 for preparing a compound of Formula (K)
a stereoisomer, or pharmaceutically acceptable salt thereof, wherein:
R 3 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 CH 3 , —CH 2 (CH 3 ) 2 , —CH(CH 3 )CH 2 CH 3 , —CH 2 CH(CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH 2 CH 2 CH═CH 2 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), —C≡CH, —CH 2 C≡CH, —CH 2 C≡C(CH 3 ), cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 , cyclopentyl-CH 2 CH 2 —, cyclohexyl-CH 2 CH 2 —, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, (2-Cl-phenyl)CH 2 —, (3-Cl-phenyl)CH 2 —, (4-Cl-phenyl)CH 2 —, (2,3-diF-phenyl)CH 2 —, (2,4-diF-phenyl)CH 2 —, (2,5-diF-phenyl)CH 2 —, (2,6-diF-phenyl)CH 2 —, (3,4-diF-phenyl)CH 2 —, (3,5-diF-phenyl)CH 2 —, (2,3-diCl-phenyl)CH 2 —, (2,4-diCl-phenyl)CH 2 —, (2,5-diCl-phenyl)CH 2 —, (2,6-diCl-phenyl)CH 2 —, (3,4-diCl-phenyl)CH 2 —, (3,5-diCl-phenyl)CH 2 —, (3-F-4-Cl-phenyl)CH 2 —, (3-F-5-Cl-phenyl)CH 2 —, (3-Cl-F-phenyl)CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, (2-Cl-phenyl)CH 2 CH 2 —, (3-Cl-phenyl)CH 2 CH 2 —, (4-Cl-phenyl)CH 2 CH 2 —, (2,3-diF-phenyl)CH 2 CH 2 —, (2,4-diF-phenyl)CH 2 CH 2 —, (2,5-diF-phenyl)CH 2 CH 2 —, (2,6-diF-phenyl)CH 2 CH 2 —, (3,4-diF-phenyl)CH 2 CH 2 —, (3,5-diF-phenyl)CH 2 CH 2 —, (2,3-diCl-phenyl)CH 2 CH 2 —, (2,4-diCl-phenyl)CH 2 CH 2 —, (2,5-diCl-phenyl)CH 2 CH 2 —, (2,6-diCl-phenyl)CH 2 CH 2 —, (3,4-diCl-phenyl)CH 2 CH 2 —, (3,5-diCl-phenyl)CH 2 CH 2 —, (3-F-4-Cl-phenyl)CH 2 CH 2 —, or (3-F-5-Cl-phenyl)CH 2 CH 2 —,
R 5 is —CH 3 , —CH 2 CH 3 , —CH 2 CH 2 CH 3 , CH(CH 3 ) 2 —CH 2 CH 2 CH 2 CH 3 r —CH(CH 3 )CH 2 CH 3 , —CH 2 CH 3 ) 2 , —CH 2 C(CH 3 ) 3 , —CH 2 CH 2 CH 2 CH 2 CH 3 , —CH(CH 3 )CH 2 CH 2 CH 3 , —CH 2 CH(CH 3 )CH 2 CH 3 , —CH 2 CH 2 CH(CH 3 ) 2 , —CH(CH 2 CH 3 ) 2 , —CH 2 CF 3 , —CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CF 3 , —CH 2 CH 2 CH 2 CH 2 CF 3 , —CH═CH 2 , —CH 2 CH═CH 2 , —CH═CHCH 3 , cis-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CH(C 6 H 5 ), —CH 2 CH═C(CH 3 ) 2 , cis-CH 2 CH═CHCH 2 CH 3 , trans-CH 2 CH═CHCH 2 CH 3 , cis-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH 2 CH═CH(CH 3 ), trans-CH 2 CH═CHCH 2 (C 6 H 5 ), —C≡CH, —CH 2 C≡CH, —CH 2 C≡C(CH 3 ), —CH 2 C≡C(C 6 H 5 ) —CH 2 CH 2 C≡CH, —CH 2 CH 2 C≡C(CH 3 ), —CH 2 CH 2 C≡C(C 6 H 5 ), cyclopropyl-CH 2 —, cyclobutyl-CH 2 —, cyclopentyl-CH 2 —, cyclohexyl-CH 2 —, (2-CH 3 -cyclopropyl)CH 2 —, (3-CH 3 -cyclobutyl)CH 2 —, cyclopropyl-CH 2 CH 2 —, cyclobutyl-CH 2 CH 2 —, cyclopentyl-CH 2 CH 2 —, cyclohexyl-CH 2 CH 2 —, (2-CH 3 -cyclopropyl)CH 2 CH 2 —, (3-CH 3 -cyclobutyl)CH 2 CH 2 —, phenyl-CH 2 —, (2-F-phenyl)CH 2 —, (3-F-phenyl)CH 2 —, (4-F-phenyl)CH 2 —, furanyl-CH 2 —, thienyl-CH 2 —, pyridyl-CH 2 —, 1-imidazolyl-CH 2 —, oxazolyl-CH 2 —, isoxazolyl-CH 2 —, phenyl-CH 2 CH 2 —, (2-F-phenyl)CH 2 CH 2 —, (3-F-phenyl)CH 2 CH 2 —, (4-F-phenyl)CH 2 CH 2 —, furanyl-CH 2 CH 2 —, thienyl-CH 2 CH 2 —, pyridyl-CH 2 CH 2 —, 1-imidazolyl-CH 2 CH 2 —, oxazolyl-CH 2 CH 2 —, or isoxazolyl-CH 2 CH 2 —,
Z is methyl, ethyl, i-propyl, n-propyl, n-butyl, i-butyl, s-butyl, t-butyl, or allyl; and
R 13 , at each occurrence, is independently selected from H, F, Cl, OH, —CH 3 , —CH 2 CH 3 , —OCH 3 , and —CF 3 .
39 . A process according to claim 32 for preparing the compound,
(2R,3S) N1-[1,3,4,5-tetrahydro-1,5-dimethyl-2,4-dioxo-2H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide,
a stereoisomer or a pharmaceutically acceptable salt thereof, comprising the steps illustrated in the following reactions,
Step (1): Intermediate 48′
(i) mixing to a solution of tert-butyl succinate ester reagent 9 (1.0 eq) in DMF (0.25 M) at zero degrees HATU (1.1 eq), then Hunig's base (4.0 eq);
(ii) stirring the mixture at zero degrees for 10 mins;
(iii) further adding to the mixture, a solution of 3 amino-1,3,4,5-tetrahydro-1,5-dimethyl-2H-1,5-benzodiazepin-2,4-dione 32 reagent in DMF (0.8 M) (1.0 eq); and stirring the reaction mixture overnight at RT;
(iv) extracting the aqueous solution twice with 30% n-hexane in ethyl acetate, washing the combined organic layers with water and brine, drying a resulting residue over magnesium sulfate and when sufficiently concentrated in vacuo; and chromatographically purifying and isolating the Compound 48′ as an amorphous white solid (92%). Rf=0.15 (7:3 n-hexane:ethyl acetate) of the following purity parameters:
1 H-NMR (CDCl 3 ): δ 7.34 (s, 4H); 6.97-6.94 (d, 1H); 5.80-5.60 m, 1H); 5.15-4.95 (m, 3H); 3.45 (s, 6H); 2.65-2.20 (m, 4H); 1.80-1.50 (m, 2H); 1.18-1.00 (m, 1H); 0.95-0.92 (d, 3H); 0.87-0.84 (d, 3H); MS (M+H) + 472.2.
Step 2:
Intermediate 48″
(i) stirring a solution of intermediate compound 48′ in 50% TEA in methylene chloride (0.15M) at RT overnight,
(ii) concentrate in vacuo, and
(iii) repeatedly wash with toluene and concentrate in vacuo to obtain solid intermediate 48″; and
Step 3:
Compound 48:;
(i) adding HATU (1.1 eq) to a solution of 48″ (1.0 eq.) in DMF (0.25 M) under N—) at 0° C., followed by Hunig's base (4.0 eq), stirring at 0° C. for 110 min, and passing anhydrous ammonia through the solution for two minutes,
(ii) following a procedure analogous to the procedure of Step 1 (iv) above, the title compound of Example 48, was prepared, exhibiting the following purity parameters,
1 H NMR (CDC 3 ): δ7.36 (s, 4H); 7.10-7.00 (d, 1H); 6.44 (s, 1H); 5.85-5.75 (m, 1H) 5.40 (m, 1H); 5.19-5.00 (m, 3H); 3.50-3.45 (d, 6H); 2.70-2.33 (m, 4H); 1.60-1.40 (m, 2H); 1.30-1.20 (m, 1H); 0.90-0.85 (q, 6H). MS (M+H)+=415.4, (M+Na)+=437.4.
40 . A process according to claim 32 for preparing a compound, a stereoisomer or pharmaceutically acceptable salt thereof selected from:
(2R,3S)N1-[1,3,4,5-tetrahydro-1,5-dimethyl-2,4-dioxo-2H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-allyl-butanediamide.
41 . A process for preparing a pharmaceutical composition comprising a compound according to the process of claim 1 , a stereoisomer, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.Join the waitlist — get patent alerts
Track US2008171735A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.